Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hs 578T | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000427 | uM | 10379.092 | 0.8816 | 0.9047 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.00213 | uM | 10379.092 | 0.9655 | 0.9730 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0107 | uM | 10379.092 | 0.9050 | 0.9241 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0533 | uM | 10379.092 | 0.9574 | 0.9665 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.267 | uM | 10379.092 | 0.9078 | 0.9264 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Erlotinib | EGFR | ErbB | 1.33 | uM | 10379.092 | 0.9322 | 0.9463 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Erlotinib | EGFR | ErbB | 6.67 | uM | 10379.092 | 0.8527 | 0.8803 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Erlotinib | EGFR | ErbB | 33.3 | uM | 10379.092 | 0.6092 | 0.6506 | 2.5811 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7477.091 | 1.0584 | 1.1012 | 1.1485 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7477.091 | 1.7006 | 2.1755 | 1.1485 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7477.091 | 1.0094 | 1.0163 | 1.1485 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7477.091 | 1.4388 | 1.7453 | 1.1485 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 7477.091 | 1.1496 | 1.2582 | 1.1485 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 7477.091 | 1.2368 | 1.4065 | 1.1485 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 7477.091 | 1.3048 | 1.5214 | 1.1485 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 13.3 | uM | 7477.091 | 1.2716 | 1.4653 | 1.1485 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 7477.091 | 1.1743 | 1.3003 | 1.1485 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0000853 | uM | 10380.092 | 1.0527 | 1.0702 | 1.4888 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000427 | uM | 10380.092 | 1.1220 | 1.1608 | 1.4888 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.00213 | uM | 10380.092 | 1.0420 | 1.0560 | 1.4888 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0107 | uM | 10380.092 | 1.0663 | 1.0881 | 1.4888 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0533 | uM | 10380.092 | 1.0392 | 1.0524 | 1.4888 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.267 | uM | 10380.092 | 1.0735 | 1.0976 | 1.4888 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 1.33 | uM | 10380.092 | 1.0454 | 1.0606 | 1.4888 | |
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 6.67 | uM | 10380.092 | 1.0164 | 1.0220 | 1.4888 |